



BREAKTHROUGH PEPTIDE THERAPEUTICS

Market Announcements Platform
Australian Securities Exchange

RICHARD HOPKINS APPOINTED PHYLOGICA CEO

PERTH, AUSTRALIA: 19 July 2013: Leading Australian peptide drug discovery company Phylogica Limited (ASX:PYC, XETRA:PH7) has appointed Dr Richard Hopkins as the company's new Chief Executive Officer as part of a broad company strategic review. He will be appointed to the Board effective immediately.

Dr Hopkins has been with Phylogica since 2006, where he has served in variety of positions, most recently as Chief Scientific Officer (CSO). Dr Hopkins has worked with the phylomer platform for over 12 years and is a founding shareholder in Phylogica. Prior to that, he held senior research roles including with the Telethon Institute for Child Health Research, Department of Medicine at the University of Western Australia and Murdoch University.

"Richard will be an excellent CEO," said Dr Doug Wilson, Chairman of Phylogica. "He has carried the company's contracts with clients and their R&D plans for some years and also held the role of Chief Operating Officer where he also managed budgets. He is a gifted communicator and well accepted internationally. He will fulfil the CEO role admirably."

As part of a wider management re-structure, Dr Paul Watt will retire as a director and transfer from CEO to take on the CSO role. This change will allow Dr Watt to focus on developing new and exciting scientific and research opportunities for the company.

Dr Wilson thanked Dr Watt for his contribution as CEO. "Paul played a major role in negotiating Phylogica's 4 discovery alliances with top 10 pharmaceutical companies, which has helped forge an international reputation for the company. The board is also very grateful to Paul for his important work and his flexibility with the re-structure. He is a very gifted and imaginative scientist and we are eager to work with him to find the optimal role for him going forward.

Mr Nick Woolf, has also announced his intention to retire as a director immediately and to step-down from his current role as Chief Financial Officer at the end of September to pursue other strategic interests. The new CFO will be Mr Graeme Boden, the current company secretary.

“Nick has been a robust supporter of the company during his three years and his contributions have been much appreciated by the Board and staff. We thank him for his dedication and commitment,” said Dr Wilson.

Dr Wilson noted the company management structure had been reorganised to position it for the on-going contractual obligations and emerging strategic opportunities. Importantly, the changes will decrease the company’s cost-base and make the company’s aspirations more achievable.

-ends-

For further information, please contact:

Rudi Michelson
Monsoon Communications
Tel + 61 3 9620 3333
rudim@monsoon.com.au

About Phylogica

Phylogica Limited (ASX: PYC) is a biotechnology company based in Perth, Australia with a world-class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics. The Company was incorporated in 2001 as a spin out from the Telethon Institute for Child Health Research (Perth, Australia) and the Fox Chase Cancer Centre (Philadelphia, USA). The Company’s drug discovery platform is based on its proprietary Phylomer[®] libraries containing over 400 billion unique natural peptides, which have been optimised by evolutionary selection to have stable drug-like structures. Phylogica offers fully integrated drug discovery services to the pharmaceutical industry utilising its Phylomer[®] libraries and proprietary screening technologies. Its current partners include Genentech (a member of the Roche Group), MedImmune (the worldwide biologics arm of AstraZeneca), Pfizer and Janssen.

About Phylomer[®] Peptides

Phylomer peptides are derived from biodiverse natural sequences, which have been selected by evolution to form stable structures, which can bind tightly, and specifically to disease associated target proteins, both inside and outside cells. Suitable targets for blockade by Phylomers include protein interactions that promote multiple diseases, such as infectious diseases, cancer, autoimmunity and heart disease. Phylomer peptides can have drug-like properties, including specificity, potency and thermal stability, and are capable of being produced by synthetic or recombinant manufacturing processes. Phylomer peptides are also readily formulated for administration by a number of means, including parenteral or intranasal delivery approaches.